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Amino Acids and mTOR Mediate Distinct Metabolic
Checkpoints in Mammalian G1 Cell Cycle
Mahesh Saqcena, Deepak Menon, Deven Patel, Suman Mukhopadhyay, Victor Chow, David A. Foster*
Department of Biological Sciences, Hunter College of the City University of New York, New York, New York, United States of America
Abstract
Objective: In multicellular organisms, cell division is regulated by growth factors (GFs). In the absence of GFs, cells
exit the cell cycle at a site in G1 referred to as the restriction point (R) and enter a state of quiescence known as G0.
Additionally, nutrient availability impacts on G1 cell cycle progression. While there is a vast literature on G1 cell cycle
progression, confusion remains – especially with regard to the temporal location of R relative to nutrient-mediated
checkpoints. In this report, we have investigated the relationship between R and a series of metabolic cell cycle
checkpoints that regulate passage into S-phase.
Methods: We used double-block experiments to order G1 checkpoints that monitor the presence of GFs, essential
amino acids (EEAs), the conditionally essential amino acid glutamine, and inhibition of mTOR. Cell cycle progression
was monitored by uptake of [3H]-thymidine and flow cytometry, and analysis of cell cycle regulatory proteins was by
Western-blot.
Results: We report here that the GF-mediated R can be temporally distinguished from a series of late G1 metabolic
checkpoints mediated by EAAs, glutamine, and mTOR – the mammalian/mechanistic target of rapamycin. R is
clearly upstream from an EAA checkpoint, which is upstream from a glutamine checkpoint. mTOR is downstream
from both the amino acid checkpoints, close to S-phase. Significantly, in addition to GF autonomy, we find human
cancer cells also have dysregulated metabolic checkpoints.
Conclusion: The data provided here are consistent with a GF-dependent mid-G1 R where cells determine whether it
is appropriate to divide, followed by a series of late-G1 metabolic checkpoints mediated by amino acids and mTOR
where cells determine whether they have sufficient nutrients to accomplish the task. Since mTOR inhibition arrests
cells the latest in G1, it is likely the final arbiter for nutrient sufficiency prior to committing to replicating the genome.
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Introduction
The vast majority of mutations that contribute to cancer cell
proliferation and survival are in genes that regulate progression
through G1 phase of the cell cycle [1,2]. A key regulatory site in
G1 is the growth factor (GF)-dependent restriction point (R),
originally described by Pardee [3], where cells receive
permissive signals to progress through G1 and divide. In the
absence of GFs, cells enter a quiescent state known as G0.
This GF-dependent R has been mapped to a site about 3 to
4hr post-mitosis in virtually all mammalian cells examined [4].
In addition to GF signals, nutrient availability and mTOR
(mammalian/mechanistic target of rapamycin) also impact on
G1 cell cycle progression [5,6]. Several texts have suggested
that R in mammalian cells is analogous to START in the yeast
cell cycle. However, yeasts are single cell organisms that
divide in response to nutrient availability, not GFs. Moreover
TOR-regulated START responds to nutrient availability [7–9].
We have hypothesized a distinct “Cell Growth” checkpoint in
late G1, where cells ensure the availability of adequate raw
materials before committing to replicating the genome and
dividing [2]. Thus, START is evolutionarily more related to the
proposed Cell Growth checkpoint rather than the GF-mediated
R.
In this report, we demonstrate that R and nutritional
checkpoints mediated by essential amino acids (EAA),
glutamine (Q), and mTOR are distinct and temporally
distinguishable. We also demonstrate that in addition to GF
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autonomy, nutrient sensing in G1 is dysregulated in cancer
cells resulting in S- and G2/M-phase arrest. In addition to
revealing differences between R and nutrient-sensitive
checkpoints, our data suggest that metabolic dysregulation
provides novel opportunities for therapeutic intervention.
Materials and Methods
Materials
Reagents were obtained from the following sources:
Antibodies against Akt, phospho-Akt (T308 and S473), S6K,
phospho-S6K (T389), 4EBP1, phospho-4EBP1 (T37/46), LC3-
II, Rb, phospho-Rb (T807/811), cyclin E, and actin were
obtained from Cell Signaling; antibody against p21 was
obtained from Santa Cruz Biotechnology; antibody against
cyclin D was obtained from BD Biosciences; and anti-mouse
and anti-rabbit HRP conjugated secondary antibodies were
obtained from Promega. DMEM (D6429), DMEM lacking Gln
(D5546), DMEM lacking Arg, Leu and Lys (D9443), dialyzed
fetal bovine serum (DFBS) (F0392), and glutamine (G7513)
were obtained from Sigma. Rapamycin was obtained from LC
Laboratories, and Torin1 was obtained from Tocris. Ultima
Gold scintillation fluid (6013681) and [3H]-thymidine
deoxyribose (TdR) (20 Ci/mMol, 1 mCi/ml) (NET-027E) were
obtained from PerkinElmer.
Cells and cell culture conditions
BJ hTERT, MCF7, MDA-MB-231, and Panc-1 cells were
obtained from the American Tissue Type Culture Collection. All
the cells were maintained in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) (Sigma).
Western blot analysis
Proteins were extracted from cultured cells in M-PER
(Thermo Scientific, 78501). Equal amounts of proteins were
subjected to SDS-PAGE on polyacrylamide separating gels.
Electrophoresed proteins were then transferred to
nitrocellulose membrane. After transfer, membranes were
blocked in an isotonic solution containing 5% non-fat dry milk in
PBS. Membranes were then incubated with primary antibodies
as described in the text. Depending on the origin of the primary
antibody, either anti-mouse or anti-rabbit HRP conjugated IgG
was used for detection using ECL system (Pierce).
Thymidine incorporation assay
To determine the progression from G1 to S-phase, cells were
labeled with 1µCi/ml [3H]-thymidine (TdR). At indicated times,
cells were washed twice with 1ml phosphate-buffered saline,
and then precipitated twice with 1ml 10% trichloroacetic acid.
The precipitates were solubilized in 0.5 ml of 0.5% SDS/0.5M
NaOH solution, and the extent of TdR incorporation was
quantified using 75 µl of sample and 3 ml of scintillation fluid.
Flow cytometric analysis
Cultured cells were washed and trypsinized. Cell
suspensions were recovered and resuspended in the following
fixing solution: 7ml 1X phosphate buffered saline, 2% bovine
serum albumin, 5mM EDTA, 0.1% NaN3. 3ml of 100% ethanol
was added drop wise. Fixed cells were centrifuged, washed,
and then resuspended in 500µl sorting buffer: 1X phosphate
buffered saline, 0.1% Triton-X 100, 2% bovine serum albumin,
5mM EDTA, 40µg/ml propidium iodide, 100µg/ml RNAse A,
and incubated at 37C for 30 min. The cells were filtered
through 70-µm mesh to remove cell aggregates. The DNA
content was analyzed by flow cytometry (FACSCalibur; Becton
Dickinson), and percentages of cells within each phase of the
cell cycle were determined using WinCycle software (Phoenix
Flow Systems).
Results
Growth factor and amino acids deprivation, as well as
mTOR inhibition induce G1 cell cycle arrest
To characterize the G1 arrest induced by GF and nutrient
deprivation, and mTOR inhibition, we used the human foreskin
fibroblast BJ hTERT cell line, which has been immortalized by
introduction of telomerase to prevent replicative senescence
[10]. BJ hTERT cells were shifted to medium lacking GF, EAA,
Q, or complete medium containing 20 µM rapamycin for 24 or
48 hr. We demonstrated previously that complete G1 arrest in
response to rapamycin required the high micro-molar doses
that are able to suppress phosphorylation of the mTORC1
substrate eukaryotic initiation factor 4E-binding protein-1 (4E-
BP1) [11]. In that study we had shown that 20 µM rapamycin is
required to completely suppress TdR incorporation in MDA-
MB-231 and MCF7 breast cancer cells. Rapamycin dose
response similar to MCF7 cells was obtained with BJ cells
(data not shown). We also demonstrated that the effect of
rapamycin was specific for mTORC1 and not due to off-target
effects. To monitor progression into S-phase, the cells were
labeled using [3H]-TdR for the final 24 hr of treatment. As
shown in Figure 1A, GF, EAA, or Q deprivation causes 50-70%
decrease in [3H]-TdR incorporation in initial 24 hr. However, by
48 hr, TdR incorporation reduced to less than 5% of control,
indicating complete cell cycle arrest under these conditions.
Rapamycin caused complete arrest at both 24 and 48 hr of
treatment.
We next examined cell cycle distribution in BJ cells by
measuring DNA content using flow cytometry. The cells were
placed in various blocking conditions for 48 hr, fixed and
stained using propidium iodide and analyzed by FACS. The
cells had a marked increase in G1 cell population at the
expense of S- and G2/M-phase cells upon serum deprivation
and to a lesser extent with rapamycin (Figure 1B). However
upon EAA and Q deprivation, BJ cells maintained their S-phase
DNA content despite the observation in Figure 1A that there
was no DNA synthesis after 48 hr of deprivation. This would
indicate that for cells in S-phase, the lack of either EAA or Q
prevents cells from progressing out of S-phase (Figure 1B).
While rapamycin led to an increase in the percentage of G1-
phase cells and a decrease in the percentage of S-phase cells,
the percentage of G2/M-phase cells remained constant –
indicating that rapamycin may also retard progression through
G2 and or M.
Metabolic G1 Cell Cycle Checkpoints
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Figure 1.  Growth factor and amino acid deprivation, as well as mTOR inhibition induce G1 cell cycle arrest.  (A) BJ hTERT
cells were plated at 20% confluence in DMEM containing 10% FBS for 24 hr at which time they were shifted to complete medium
(CM) or various blocking conditions [-GF, -EAA, -Q, +Rapamycin (20 µM)] for 24 or 48 hr. The blocking conditions for Q used
DMEM lacking Q; and for EAA, DMEM lacking Leu, Lys, and Arg as described in Material and Methods. The CM contained 10%
dialyzed FBS (DFBS) instead of 10% FBS. Cells were labeled with [3H]-TdR for the final 24 hr of treatment, after which the cells
were collected and the incorporated label was determined by scintillation counting as described in Materials and Methods. Values
were normalized to the cpm for CM, which was given a value of 100%. Total cpm for the CM controls was 60,512 +/- 6529 for the 24
hr time point and 80,427 +/- 3567 for the 48 hr time point. Error bars represent the standard deviation for experiments repeated at
least two times. (B) BJ cells were plated and shifted to CM or various blocking conditions for 48 hr as in (A), after which the cells
were harvested and analyzed for cell cycle distribution by measuring DNA content/cell as described in Materials and Methods. Error
bars represent the standard error from independent experiments repeated four times. (C) To investigate the kinetics for progression
into S-phase, BJ cells were plated and shifted to blocking conditions for 48 hr as in (A). Cells were subsequently released by shifting
to complete medium, and pulsed with [3H]-TdR at the indicated time points for 1 hr – after which the cells were collected and the
incorporated label was determined. Error bars represent the standard error of mean for experiments repeated three times.
doi: 10.1371/journal.pone.0074157.g001
Metabolic G1 Cell Cycle Checkpoints
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To determine whether cells are capable of re-entry into cell
cycle, we measured the kinetics for progression into S-phase
upon release from various arrested states. In brief, cells were
placed in various blocking conditions for 48 hr. Cells were then
released from the block by replacing with complete medium,
and pulsed with [3H]-TdR for 1 hr at indicated time points (0 to
28 hr). As shown in Figure 1C, cells starting from G0 (GF
deprivation) took approximately 16 hr to enter the S-phase.
Cells starting from rapamycin block also entered the S-phase
after 16 hr. Surprisingly, cells starting from EAA or Q block
began synthesizing DNA with a longer lag phase of 18 to 20 hr.
While there are a small fraction of cells in S-phase (5-15%)
with various blocking conditions as seen by flow cytometry
(Figure 1B), the prolonged lag phase along with low baseline
and sharp transition indicates that TdR incorporation occurs
predominantly from G1-phase cells released from blocking
conditions into S-phase (Figure 1C). Our observation for the
time required to traverse from G0 to S-phase is similar to what
has been described previously [12–14]. Thus, the kinetic
analysis shows that cells are able re-enter the cell cycle upon
release from various blocking conditions. These data also
reveal differences in recovery times after being subjected to
EAA, Q and GF deprivation; however they do not provide
insight as to the temporal relationships of the different blocking
mechanisms.
GF, EAA, Q, and rapamycin mediated G1 cell cycle
arrests are distinct and distinguishable
In order to distinguish G1 cell cycle arrest caused by different
blocking conditions, we performed a series of sequential
blocking experiments. In brief, cells were exposed to various
blocking conditions for 48 hr to cause complete arrest. At this
point, the first block was removed and a second block was
applied along with [3H]-TdR for 24 hr. If the second block
applied is either at the same point or downstream of the first
block, then [3H]-TdR incorporation should not occur. However,
if the second block site is upstream of the first block, then the
cells should progress into S-phase and incorporate the label.
The extent of [3H]-TdR incorporated by cells released into
complete medium after various first blocks was considered to
be 100%. As shown in Figure 2A, when GF deprivation was
applied as the first block and when either EAA or Q deprivation,
or rapamycin treatment were applied as second blocks, there
was very little [3H]-TdR incorporation- indicating that the GF
arrest site is either upstream or at the same site as other
blocking conditions. When EAA deprivation was applied as the
first block (Figure 2B), followed by a second block of GF
deprivation, increased [3H]-TdR incorporation was seen.
However, with either Q deprivation or rapamycin treatment as
the second block, no significant [3H]-TdR incorporation was
observed. When Q deprivation was applied as the first block
(Figure 2C), only rapamycin treatment as the second block
prevented progression into the S-phase, whereas a second
block of GF or EAA deprivation failed to arrest the cells. Lastly,
when rapamycin treatment was applied as a first block followed
by GF, EAA, or Q deprivation as the second block, there was
an increase in [3H]-TdR incorporation in all the cases, indicating
that all the blocks are upstream of rapamycin arrest site (Figure
2D). Taken together, the data indicates that the arrest sites
mediated by various blocking conditions are distinguishable, in
the order of GF → EAA → Q → mTOR (Figure 2E).
Temporal mapping of the G1 cell cycle checkpoints
To better understand the temporal map shown in Figure 2E,
we examined the ability of EAA, Q, and rapamycin to block G1
cell cycle progression after release from G0. Cells were
synchronized in G0 using serum deprivation for 48 hr. The cells
were reinitiated into cell cycle by providing complete medium
and [3H]-TdR. At indicated time points, cells were shifted to
various blocking conditions to determine the point when
blocking no longer prevented entry into S-phase (schematic
shown in Figure 3A). As shown in Figure 3B, starting from G0,
EAA or Q withdrawal until 12 hr caused the cells to arrest in
G1, after which their withdrawal did not arrest the cells as
evidenced by increased TdR incorporation. Addition of
rapamycin continued to suppress TdR incorporation until 16 hr
after release from G0, as did a catalytic inhibitor of mTOR –
Torin1. This suggests that EAA and Q checkpoints are 12 hr
from G0 and are upstream from rapamycin-mediated arrest,
which apparently is very close to the G1/S border since it takes
16 hr from the time of restoring GF to increased TdR
incorporation (Figure 1C).
Restriction point and metabolic checkpoint arrest lead
to differential patterns of cell cycle regulator
expression and phosphorylation
The data in Figures 2 and 3 indicate a temporal difference in
the ability of GF, EAA, and Q deprivation, and rapamycin to
arrest cells in G1. To further establish that the cell cycle
checkpoints are distinct – especially between the EAA and Q
checkpoints, which apparently are temporally very close to
each other – we examined the impact on cell cycle regulatory
signals. A key cell cycle regulatory signaling pathway is
mediated by phosphatidylinositol-3-kinase (PI3K) and Akt
signals that impact on mTOR [15]. Akt is phosphorylated at
Thr308 in response to GF stimulation of PI3K activation [16].
As expected, GF deprivation led to a decrease in Akt
phosphorylation at Thr308 (Figure 4A and 4B). There was also
a decrease in Akt phosphorylation at Ser473 - a downstream
target of mTORC2 [17]. There was a marked decrease in
phosphorylation of p70-S6 kinase (p70S6K) and a smaller
decrease in the phosphorylation of4EBP1 upon GF deprivation.
In contrast, EAA and Q deprivation had no effect on Akt
phosphorylation at either Thr308 or Ser473, indicating no effect
on PI3K or mTORC2 activity (Figure 4A and 4B). However,
both EAA and Q deprivation did suppressp70S6K
phosphorylation. Interestingly, EAA deprivation suppressed 4E-
BP1 phosphorylation, whereas Q deprivation did not –revealing
a differential impact on mTORC1 in response to EAA and Q
deprivation (Figure 4A and 4B). Treatment of cells with
rapamycin led to no noticeable change in Akt phosphorylation
at either Thr308 or Ser473. As expected, rapamycin
suppressed the phosphorylation of both mTORC1
substratesp70S6K and 4EBP1. We also examined the impact of
nutrient and GF deprivation on autophagy by looking at
increased levels of the autophagy marker LC3-II. Significantly,
Metabolic G1 Cell Cycle Checkpoints
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Figure 2.  GF, EAA, Q, and rapamycin mediated G1 cell cycle arrests are distinct and distinguishable.  (A–D) BJ hTERT cells
were plated and shifted to various first blocking conditions for 48 hr as in Figure 1A. The cells were subsequently shifted to CM or
different second block conditions containing [3H]-TdR for 24 hr, after which the cells were collected and the incorporated label was
determined. Error bars represent the standard error for the experiment repeated at least four times. (E) Schematic model showing
relative positions of different metabolic checkpoints relative to R (not drawn to represent precise time scales). G1-pm is post-mitotic
phase in G1, G1-ps is pre-S phase of G1 [4].
doi: 10.1371/journal.pone.0074157.g002
Metabolic G1 Cell Cycle Checkpoints
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Figure 3.  Temporal mapping of the metabolic checkpoints from G0.  (A) Schematic representation of the experiment shown in
(B). (B) BJ cells were plated as in Figure 1A for 24 hr. Cells were synchronized in G0 by shifting to DMEM+1mM Q lacking GF for
48 hr. The cells were released from G0 by shifting to CM containing DMEM (1mM Q) and 1 µCi/ml [3H]-TdR. Various blocking
conditions along with [3H]-TdR were applied at indicated time points. After 36 hr from the release from G0, cells were collected and
the incorporated label was determined. This experiment utilized DMEM with reduced Q (1 mM vs. 4 mM) because Q withdrawal
following DMEM with high Q did not give strong G1 arrest. Error bars represent the standard error for experiments repeated three
times.
doi: 10.1371/journal.pone.0074157.g003
Metabolic G1 Cell Cycle Checkpoints
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EAA, but not Q deprivation increased LC3-II levels. As
expected, rapamycin treatment, which is known to induce
autophagy [18], also led to increased levels of LC3-II (Figure
4A and 4B). Thus, although all of the conditions used here
cause G1 cell cycle arrest, they impact differentially on PI3K
and mTOR kinase activity supporting the hypothesis that the
checkpoints identified represent distinct sites in G1 – especially
between the two amino acid sites.
We next examined the impact of different blocking conditions
on known G1 cell cycle regulators. For this approach, cells
were placed under various blocking conditions for 48 hr and
subsequently released by restoring complete medium. Cell
lysates were collected at indicated time points and analyzed for
phosphorylated-Rb (P–Rb), Rb, cyclin D, and p21 using
Western blot analysis. For cells arrested by GF deprivation, we
see much less Rb protein and P–Rb Ser807/811 at time 0, but
there was a dramatic increase in both Rb protein and P–Rb
Ser807/811 levels from 11hr onwards (Figure 4C and 4D). A
similar Rb profile was seen with cells starting from a Q
deprived state. However, for cells starting from the EAA
deprived state, there were high levels of Rb at time 0 that did
not change much after restoring the EAA. This effect was
clearly distinct from that seen with Q deprivation, where there
were much lower levels of both Rb and P–Rb. Rapamycin
treatment did not significantly reduce the levels of Rb protein or
P–Rb - indicating that cells had arrested in late-G1 where Rb is
already hyperphosphorylated. Passage through R correlates
with an increase in cyclin D levels [19]. Upon restoration of
complete medium to GF-deprived cells, there was a significant
increase in the level of cyclin D1 between 5 and 14 hr (Figure
4E). In contrast, cells starting from EAA, Q, or rapamycin
blocking conditions showed lesser changes in cyclin D1 levels
– indicating a clear distinction between the GF-dependent R
and the later nutrient-dependent metabolic checkpoints. Cells
starting from all blocking conditions showed very similar cyclin
E profiles, with cyclin E levels increasing from 11 hr onwards
(data not shown). The CDK inhibitor p21 plays complex roles in
controlling G1 cell cycle progression [20,21]. For cells starting
from GF-deprived state, there was very little p21 at time 0 but
its level increased significantly by 2 hr and then dropped after
7hr (Figure 4F). The drop in p21 levels coincided with the
increase in cyclin D levels and Rb phosphorylation at S807/811
(Figure 4C and 4E). With EAA and Q deprivation, there were
very low levels of p21 at time 0 for EAA and high levels with Q
– again clearly distinguishing these two checkpoints. With
rapamycin block there was very little p21 at time 0 that was
maintained over the 20 hr time course. Collectively, the data in
Figure 4 reveal differential impact of various blocking
conditions on the expression and phosphorylation of cell cycle
regulatory proteins. While the data do not provide mechanistic
insight into cell cycle arrests mediated by different blocking
conditions, they clearly establish that the cell cycle arrest
caused by various blocking conditions represent unique cell
cycle checkpoints.
Metabolic checkpoints are dysregulated in cancer cells
Complementing mutations required for transformation [2]
suggest that in addition to GF autonomy, cancer cells may also
have dysregulated metabolic checkpoints to allow progression
through both R and the late-G1 metabolic cell growth
checkpoints. To further characterize the impact of GF and
nutritional inputs in cancer cells, we examined cell cycle
distribution in three human cancer cell lines. Cells were placed
in various blocking conditions for 48 hr and analyzed by flow
cytometry. MCF7breast cancer cells had a marked increase in
G1 cell population at the expense of S-phase cells with serum
or amino acid deprivation and rapamycin treatment (Figure 5A
and 5D top panel). The G2/M-phase cells remained constant
indicating a G2/M-phase arrest of cells as was observed for BJ
cells deprived of EAAs in Figure 1B. The BJ cells deprived of Q
displayed an S-phase and G1 phase arrest, but not a G2/M
arrest (Figure 1B) indicating a differential sensitivity to EAA and
Q for the MCF7 breast cancer cells. In stark contrast to both
the BJ cells and the MCF7 cells, MDA-MB-231 breast and
Panc-1 pancreatic cancer cell lines displayed a dramatic loss of
any G1-phase arrest in response to both EAA and Q
deprivation(Figure 5B, 5C, and 5D middle and lower panel).
Both of these cell lines retained a G1 arrest in response to
serum withdrawal. This observation supports the hypothesis
that the cells have a mechanism for arresting in S- and G2/M-
phase upon EAA and Q deprivation. Importantly, it also
demonstrates that the ability of EAA and Q to arrest in G1 has
been lost in the MDA-MB-231 and Panc-1 cells. Rapamycin
caused an increase in the G1 cell population in all the cell lines
tested, indicating that inhibition of mTORC1 activity is sufficient
to cause G1 cell cycle arrest. As with the BJ cells (Figure 1B),
rapamycin also appeared to retard cell cycle progression in
G2/M. These observations indicate that EAA and Q sensing
acts through separate mechanism than rapamycin treatment or
GF sensing to cause G1 arrest, and that metabolic
deregulation in the MDA-MB-231 and Panc1, but not the
MCF7, cells causes override of G1 cell cycle arrest upon amino
acid deprivation.
Discussion
In this report, we have provided evidence that the GF-
mediated R and nutrient-mediated metabolic checkpoints are
distinct and distinguishable. Sequential blocking experiments
show that R is upstream of two amino acid checkpoints that are
upstream from a checkpoint mediated by mTOR. Although the
checkpoints mediated by EAA and Q were temporally close,
they could be distinguished by sequential blocking and by
distinct profiles of cell cycle regulatory protein expression and
phosphorylation. Suppression of mTOR with rapamycin
blocked cell cycle progression significantly later in G1 than
amino acid deprivation. Collectively, this study distinguishes
the GF-dependent R, which assesses whether it is appropriate
for the cell to divide, from a series of metabolic checkpoints late
in G1 that determine whether division is feasible. In addition to
mediating unique late-G1 checkpoints, our data also reveals
novel sensing requirements for EAA and Q in S- and G2/M-
phase of the cell cycle. Using Swiss 3T3 cells, Yen and Pardee
had previously found that GF deprivation led to mid-G1 arrest
whereas isoleucine deprivation caused late-G1 and S-phase
Metabolic G1 Cell Cycle Checkpoints
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Figure 4.  Restriction point and metabolic checkpoint arrest lead to differential patterns of cell cycle regulator expression
and phosphorylation.  (A) Cells were plated at 30% confluence in 10-cm plates in DMEM containing 10% FBS. After 24 hr, the
cells were shifted to CM or blocking conditions for 4 hr, at which time the cells were harvested and the levels of the indicated protein
or phosphoprotein was determined by Western blot analysis. The data shown are representative of experiments repeated at least
two times. (B) Quantitative analysis of relative protein levels for Western blots shown in (A) using ImageJ software. (C–F) BJ cells
were plated and shifted to various blocking conditions for 48 hr as in Figure 1A. The cells were subsequently released by shifting to
CM, and the cells were harvested and lysates collected at indicated time points. The levels of the indicated protein or
phosphoprotein were determined by Western blot analysis. The data shown are representative of experiments repeated at least two
times. Also shown in the line graphs are the kinetic analyses of relative protein levels normalized to actin and quantitated using
ImageJ.
doi: 10.1371/journal.pone.0074157.g004
Metabolic G1 Cell Cycle Checkpoints
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Figure 5.  Metabolic checkpoints are dysregulated in cancer cells.  MCF7 (A), MDA-MB-231 (B), and Panc-1 (C) cells were
plated at 20% confluence in 10-cm plates in DMEM containing 10% FBS. After 24 hr, the cells were shifted to CM or various
blocking conditions for 48 hr, at which time the cells were harvested, fixed, stained with propidium iodide, and analyzed for
distribution in different phases of cell cycle by measuring DNA content/cell as described in Materials and Methods. Error bars
represent the standard error from independent experiments repeated four times. Table with the mean and standard error for the
graphs is also shown. (D) Representative flow histograms showing increases in S- and G2/M-phase cell population upon EAA and
Q deprivation in MDA-MB-231 and Panc-1 cells.
doi: 10.1371/journal.pone.0074157.g005
Metabolic G1 Cell Cycle Checkpoints
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arrest [22]. This result more closely approximates the findings
reported here with the human BJ fibroblasts.
It was somewhat surprising that inhibiting mTOR blocked cell
cycle progression downstream of EAA. It is well established
that mTORC1 is responsive to EAA [23]. Thus, it was
anticipated that the absence of EAA would block cell cycle
progression at the same place as rapamycin. This was clearly
not the case – there was a two-hour difference in the time it
took for EAA deprivation to no longer prevent progression to S-
phase relative to rapamycin (Figure 3B). However, mTORC1 is
also responsive to glucose [24], ATP levels [25], and
phosphatidic acid [26], a critical intermediate in the synthesis of
membrane lipids [27–29]. Thus, mTOR may not be fully active
until it has sensed sufficient glucose, ATP, lipids, in addition to
EAA. Thus mTOR likely serves as a master regulator that
senses complete nutritional sufficiency before committing to
replicating the genome.
An important conclusion from this study is the distinguishing
of growth factor-dependent R in mid-G1 from late-G1 metabolic
checkpoints that control entry into S-phase. The point in G1
where the cells are no longer sensitive to the withdrawal of
growth factors (R) was mapped by Zetterburg and colleagues
to about 3.5 hr in virtually all mammalian cells tested [4]. The
metabolic checkpoints downstream from R in this report are
similar to a series of checkpoints in yeast collectively known as
START [7,30], where nutritional sufficiency is evaluated in a
TOR-dependent manner in yeast [8,9]. R has commonly been
referred to as the mammalian equivalent of START, but as
shown here, the metabolic checkpoints that correspond with
START are clearly distinguishable from the growth factor-
dependent R. It is likely that R evolved much later than START
as a means for multicellular organisms to regulate proliferation
through intercellular communication.
Part of the controversy over the location of a growth factor-
dependent R is that different groups have reported
responsiveness to growth factors later in G1 than described by
Zetterberg [4]. Notably Pledger and Stiles reported that PDGF
could stimulate quiescent cells to “competence” with a short
duration of treatment [31]. These competent cells could then be
induced to progress through the remainder of G1 by
“progression” factors like insulin-like growth factor-1 (IGF1)
[31]. Similar studies with hepatocytes induced from quiescence
showed a growth factor dependence that likely was extended
into later stages of G1 [32,33]. The major distinction between
these studies and Zetterberg’s work was that the Zetterberg
study followed cells from mitosis, whereas the other studies
looked at cells leaving quiescence. Thus, cells starting from
quiescence or G0 and cells starting from mitosis apparently
have different needs for progression to S-phase. What was
clear from the Zetterberg study was that after approximately
3.5 hr post mitosis, if serum growth factors were removed, cells
did not enter quiescence and proceeded through S-phase to
mitosis without any additional growth factor stimulation. In our
double block experiments (Figure 2), the cells arrested by
amino acid depletion or rapamycin could proceed to S-phase in
the absence of growth factors upon restoration of amino acids
or removal rapamycin. This is especially relevant for the mTOR
checkpoint, since mTOR is activated in response to IGF1 and
other growth factors. Importantly, the cells that arrested in G1
in response to amino acid deprivation and rapamycin, like in
the Zetterberg study, were coming from mitosis, not
quiescence, and therefore did not need growth factors to
proceed to S-phase. This would indicate that under conditions
where cells have passed through mitosis and avoided
quiescence, mTOR does not need additional growth factor
stimulation. However, this is apparently not the case when cells
are coming out of quiescence where further stimulation of
mTOR by IGF1 may be required.
GF autonomy is one of the more significant hallmarks in
cancer [34]. However, it has been suggested that mutations
leading to elevated mTOR kinase activity are the most common
mutations in observed human cancer [35,36]. Moreover,
dysregulation of cellular metabolism is considered as an
emerging hallmark of cancer [37]. Several oncogenes and
survival signals have been shown to directly upregulate
glycolytic enzymes and induce metabolic reprogramming
[38–40]. Consistent with this emerging role for metabolism in
cancer cells, we have demonstrated here that nutrient sensing
metabolic checkpoints are dysregulated in cancer cells.
Surprisingly, MDA-MB-231 breast cancer cells and Panc-1
pancreatic cancer cells deprived of EAA and Q arrested in S
and/or G2/M-phase – indicating an override of the G1 arrest
observed in normal BJ fibroblasts and MCF7 breast cancer
cells. Significantly, both the MDA-MB-231 and Panc1 have
mutant K-Ras. Thus, the late-G1 metabolic checkpoints, like R,
are apparently dysregulated as well – perhaps as a
consequence of mutant K-Ras signals. Of interest was the
apparent “freeze” in cell cycle progression in the BJ cells in
response to amino acid deprivation – indicating that collection
of cells in S- and G2/M-phase in cancer cells is a property of
normal cells. In addition to genetic defects that confer
autonomy to GF signaling, we hypothesize that specific genetic
mutations override the late-G1 nutritional checkpoints causing
them to arrest in S- and G2/M-phase of the cell cycle, where
we have shown that additional amino acid sensing occurs
through as yet unknown mechanisms. Cancer cells arrested in
S- and G2/M-phase are uniquely sensitive to the apoptotic
insult of DNA damaging agents. Thus, synthetic lethality
created by interfering with Q utilization and phase-specific
cytotoxic drugs could provide novel therapeutic opportunities
that kill cells arrested in S- and G2/M-phase.
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